The Dutch group is ripe for a takeover, and while Thermo Fisher has to be the likeliest candidate for acquirer there are a number of potentially interested parties.
A shift to higher-growth systems and a tie-up with Illumina are sensible moves, but will take time to pay off.
New data could change liquid biopsy guidelines and boost sales, though regulatory approval would not be a bad idea.
The data are positive, but might not do much for the company’s sales.
Syncona might have hoped for a bigger payday with the prostate imaging specialist, but it has plenty more irons in the fire.
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
A new player has entered the liquid biopsy game.
The US FDA granted seven approvals in two days last week, including an eagerly awaited thumbs-up for Novartis’s gene therapy Zolgensma.
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.